The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Filter
Locations
Result types
Type of company
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Lock keywords
Exclude keywords
Optional keywords
London, United Kingdom
11-50 Employees
2013
London In Vitro Diagnostics Co-operative is a partnership between Imperial College London and Imperial College Healthcare NHS Trust. We are one of four NIHR centres in England that generate evidence to support diagnostic test development. It is a pan-London and South East initiative, led by MedCity. London IVD are a key partner, alongside UCL and Queen Mary’s and we bring our expertise in diagnostics related evidence generations to the partnership. The idea is a ‘one-stop-shop’ platform to stimulate growth of diagnostic companies by enabling easy and comprehensive access to the relevant capabilities offered by the partner organisations. Manufacturing and other capabilities will also be included in the future. In addition to teaching the fundamentals of evidence to innovators, London IVD hosts individual sessions with innovators, reviewing where they are in terms of evidence supported value propositions and what the next step might be to optimise their route to (the NHS) market. In the longer term, we will be working with our partners to offer this more widely to any aspiring innovators nationally as well as internationally.
+
Featured
About Us - London In Vitro Diagnostics Co-operative
... London In Vitro Diagnostics Co-operative is a partnership between Imperial College London and Imperial College Healthcare NHS Trust. We are one of four NIHR centres in England that generate evidence to support diagnostic test development. ...
Belgium
1-10 Employees
2016
Started in 2016, X4C is a spin-off company from the Brussels University (ULB), Belgium. We are proud of our scientific origins, and we constantly keep our R&D at the highest level, while understanding and supplying our customers with highly performing products and services. X4C Rue Auguste Piccard, 48 6041 Gosselies Belgium. We like collaborations, because we are convinced that the success of a project is a perfect combination of our and our customers expertise.
+
Featured
X4C offers innovative molecular surface coatings for high-end applications in In Vitro Diagnostics.
... X4C offers innovative molecular surface coatings for high-end applications in In Vitro Diagnostics. ...
+
Featured
In Vitro Diagnostic Instruments | Tricontinent
... OEM products for In Vitro Diagnostic ✓ Syringe Pumps ✓ Liquid Handling Robots ✓ Rotary Valves ✓ Syringes ► precision and ...
New York, United States
51-100 Employees
1998
For more than two decades, Kalorama Information has been a leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), imaging, biotechnology, healthcare, medical devices, and pharmaceuticals. Kalorama continues to be the leading global publisher of market studies on healthcare industries. Our comprehensive quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers. In addition to having customers among top companies in healthcare, we are routinely solicited by the media for market data and understanding of topics. Our research team is committed to serving the information needs of professionals in the biotechnology, diagnostics, healthcare, medical devices, and pharmaceuticals markets, at all levels of management, in all sizes of companies. Bruce Carlson is a recognized voice offering commentary on the in vitro diagnostics and medical device marketplace. Melissa Elder Melissa Elder, one of the principals of Mountaintop Medical, LLC, is a key pharmaceutical analyst at Kalorama and author of over one hundred market research studies in the healthcare marketplace. Kalorama Information’s reports track medical market trends, survey market players, and provide a comprehensive analysis of each market with both the vital market data and cogent, plain-English interpretation and insight.
+
Featured
The Worldwide Market for In Vitro Diagnostic Tests, 15th Edition
... The Worldwide Market for In Vitro Diagnostic Tests, 15th ...
+
Featured
In-Vitro Diagnostics Products | Epitope Diagnostics Inc.
... In-Vitro Diagnostics Products | Epitope Diagnostics Inc. ...
West Oxfordshire, United Kingdom
1-10 Employees
We are working with clinicians and Key Opinion Leaders in Oxford and Birmingham to develop and deliver easy-to-use diagnostic devices that will transform the cost, speed and deployability of In Vitro Diagnostics to meet critical unmet needs. We are also working with the UK National Physical laboratory on novel methods of calibration. We are always on the look-out for creative, driven and enthusiastic people to join the team. In particular, Surface Enhanced Raman Spectroscopy (SERS) offers enhanced sensitivity compared to ‘traditional’ Raman Spectroscopy, and moreover, the opportunity to ‘tune’ the test to be more sensitive to specific diseases. We believe this will enable target diseases to be rapidly diagnosed from urine at low cost, displacing blood or other tests (cystoscopy, imaging) as a first diagnostic. We focus on enabling testing at the Point-of-Need, although the test could be ‘read’ either locally at a clinic, or in a Central Laboratory. We focus on how to extend the viable test life of urine samples to enable extended periods between the sample being obtained and the test sample ‘read’. We focus on the whole workflow and are already discussing how we will integrate with widely used middleware solutions to disseminate the data.
+
Featured
A new light in In Vitro Diagnostics
... at the point-of-need to disrupt a $95bn marketMultiple diagnoses from a spectral signature of urine Previous Next A new light in In Vitro Diagnostics Defining ‘molecular fingerprints’ using Surface Enhanced Raman Spectroscopy and Machine Learning enables a step-change in sensitivity, […] ...
Baar, Switzerland
1-10 Employees
2015
Our team and organization are dedicated to bring you the best of advice and support for your strategic business expansion. Based on over 100 years of experience in the diagnostic market, on product development, international marketing, product launches and strategic business alliances, we can help you decide on the right way forward and help you execute your plans. With more than 40 years of experience, Tobias is an astute and accomplished businessman as well as scientist. Highly skilled in conceptualizing, developing, and implementing comprehensive global business plans for new and innovative products. In positions as International Product Manager and CEO, Johan has focused on initiating, financing, developing products and concepts in Cardiology in MedTech and POC IVD.
+
Featured
POC In Vitro Diagnostics consulting - Expand Healthcare Consulting
... Point of care in vitro diagnostics consulting (POC IVD Consulting). Cardiac biomarkers such as Troponin, BNP, NT-proBNP and D- ...
Schwerin, Germany
11-50 Employees
2005
We are different from our competitors in our ability to provide customers with products that are tailored to their geographical region and needs. Our products are based on scientific evidence and intensive in-house researchand development – 35% of our staff hold a PhD or a postgraduate degree in science. Our point-of-care products and our laboratory tests cater to every diagnostic laboratory and health care professional`s needs. The goal is the development of a test system for the parallel determination up to 100 allergens, as well as a rapid test, which allows to determine the sensitization to one or more allergens/ allergen components by just a few drops of capillary blood directly in the doctor’s office. Products are reliable, quality is at its best and our customers are satisfied. In fact, they may offer all types of pokies, including video poker and other casino games. The way that any gamer can figure out which site will offer the best pokies is by looking at the way that the free pokies work. DST develops and manufactures innovative diagnostic solutions for laboratory and point-of-care (POC) testing.
+
Featured
Innovative In-Vitro Diagnostic Solutions
... Home DST - Innovative In-Vitro Diagnostic ...
Mumbai, India
11-50 Employees
2021
Automated Immunoassay Analyzer from blood collection tube with the all-in-one cartridge system. Boditech is a 23-year-old company providing innovative & reliable diagnostic solutions for professional use. Established in the year 2021, the company has its Head office located in Mumbai, Maharashtra. We have a field staff stationed in numerous parts of India along with a large network of distributors to provide technical assistance, customer support and most importantly, to attend our customers on priority. Eastern Business District – A314, LBS Road, Bhandup West, Mumbai 400078.
+
Featured
Boditech Med Inc.
... Boditech Med provides reliable In-Vitro Diagnostic Solutions for everyone at anywhere, and anytime. ...
Technologies which have been searched by others and may be interesting for you:
Some interesting numbers and facts about the results you have just received for In-Vitro Diagnostics
| Country with most fitting companies | United States |
| Amount of fitting manufacturers | 352 |
| Amount of suitable service providers | 278 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 1975 |
| Youngest suiting company | 2021 |
In-Vitro Diagnostics (IVD) encompasses the broad spectrum of medical devices and diagnostic technologies used to perform tests on human biological samples, such as blood, tissue, or urine, outside the human body, in a controlled environment. These diagnostics are pivotal in the healthcare domain, as they provide critical insights into the health status of an individual, facilitating early detection, monitoring, and management of diseases. IVDs range from simple home-use tests, such as glucose monitors and pregnancy tests, to complex laboratory-based systems that detect and quantify specific genetic markers, pathogens, or the presence of certain antibodies. The role of IVD in healthcare is multifaceted, significantly impacting clinical decision-making by providing data that is essential for diagnosing conditions, predicting disease progression, deciding on the course of treatment, and monitoring the effectiveness of therapeutic interventions. Moreover, IVD technologies have evolved rapidly, integrating with digital health and artificial intelligence to enhance the precision, efficiency, and predictive value of diagnostic tests. This evolution has not only improved patient outcomes through personalized medicine but also contributed to public health monitoring and management of infectious diseases, illustrating the critical role of IVD in advancing healthcare, enhancing disease management, and ultimately, improving the quality of life.
1. Early Detection and Diagnosis
: In-vitro diagnostics (IVD) offer the significant advantage of detecting diseases and health conditions early, even before symptoms appear. This early detection can lead to timely intervention, improving the chances of successful treatment and reducing the overall burden on healthcare systems.
2. Cost-Effectiveness
: Compared to many traditional diagnostic methods, IVD can be more cost-effective in the long run. By enabling early diagnosis and monitoring of diseases, IVD helps in reducing the need for more expensive treatments and hospitalizations, thus saving costs for both patients and healthcare providers.
3. Precision and Accuracy
: IVD technologies provide high levels of precision and accuracy in results, which is critical for the effective management of diseases. This accuracy ensures that patients receive the most appropriate treatment, reducing the risk of adverse reactions and increasing the likelihood of positive outcomes.
4. Personalized Medicine
: IVD plays a crucial role in the field of personalized medicine, allowing for treatments to be specifically tailored to individual patients based on their genetic makeup. This customization enhances the effectiveness of treatments and minimizes side effects, leading to better patient care and outcomes.
While evaluating the different suppliers make sure to check the following criteria:
1. Regulatory Compliance and Certifications
Ensure the supplier meets all relevant regulatory standards and holds necessary certifications for their products, such as FDA approval or CE marking in Europe.
2. Product Quality and Reliability
Evaluate the quality and reliability of the diagnostics products through peer reviews, clinical trial results, and performance evaluations.
3. Range of Products Offered
Consider suppliers with a comprehensive range of diagnostics products that can cater to your specific testing needs and preferences.
4. Technical Support and Service
Assess the level of technical support and customer service provided, including training for your staff, maintenance services, and the availability of customer service.
5. Supply Chain Stability
Check the supplier's ability to consistently supply products without delays, ensuring there are contingency plans in place for supply chain disruptions.
6. Cost-effectiveness
Compare the cost of products and services, taking into account the total cost of ownership, including product price, shipping, and any additional service fees.
7. Innovation and Technology Advancement
Choose suppliers who invest in research and development to offer innovative solutions that can improve diagnostic accuracy and patient outcomes.
In the pharmaceutical industry, in-vitro diagnostics (IVD) play a critical role in the drug development process. Companies utilize IVD technologies to streamline the discovery and evaluation of novel drugs by efficiently testing drug efficacy and safety on biological samples. This not only accelerates the development timeline but also enhances the precision of drug effects, facilitating personalized medicine approaches. Healthcare providers leverage IVD for improved patient management, particularly in the realms of disease diagnosis and monitoring. By integrating IVD solutions, hospitals and clinics can offer rapid and accurate diagnostic services, enabling timely and tailored treatment strategies. This use case extends to monitoring chronic conditions, where regular IVD tests help in adjusting treatment plans based on patient progress, significantly improving outcomes. In the agricultural sector, IVD technologies find applications in ensuring food safety and animal health. Agribusinesses employ these diagnostics to detect pathogens and contaminants in food products, thereby preventing disease outbreaks. Similarly, veterinary diagnostics, a branch of IVD, aids in the early detection of diseases in livestock, facilitating prompt intervention and reducing the spread of zoonotic diseases. Research and academic institutions utilize IVD for studying disease mechanisms and developing novel diagnostics. Through the use of IVD, researchers can conduct high-throughput screening of biological markers, contributing to advancements in understanding disease pathology and the identification of new diagnostic targets. This collaboration between IVD manufacturers and research entities drives innovation in diagnostic methodologies, expanding the capabilities of modern medicine.
In-Vitro Diagnostics (IVD) technology currently spans across various Technology Readiness Levels (TRLs), predominantly positioned at TRL 9, reflecting their comprehensive validation and widespread adoption in clinical settings. This advanced TRL status is underpinned by the extensive technical maturation and validation IVD technologies have undergone, including rigorous clinical trials, regulatory approval processes, and their integration into healthcare systems worldwide. The ability of IVD to provide critical diagnostic information from samples outside the human body, such as blood or tissue, has been significantly enhanced by technological innovations like molecular diagnostics, point-of-care testing, and the integration of digital health technologies. These advancements have improved the sensitivity, specificity, and user-friendliness of IVDs, enabling rapid, accurate diagnoses and facilitating personalized medicine. Moreover, the continuous evolution and refinement of these technologies, driven by ongoing research and development, have solidified their reliability and efficacy in diagnosing a wide range of conditions, from infectious diseases to cancer and genetic disorders. The high TRL of IVDs reflects their proven ability to meet stringent healthcare needs reliably, underscored by their technical sophistication and the pivotal role they play in modern healthcare systems.
In the short-term, advancements in in-vitro diagnostics (IVD) are expected to center around the integration of digital technologies and artificial intelligence (AI) to enhance diagnostic accuracy and speed. Compact, point-of-care devices capable of delivering rapid results will become more widespread, particularly for infectious diseases and chronic condition monitoring. This phase will also see the expansion of telehealth services, where IVD tools are connected to healthcare systems, allowing for remote diagnosis and patient management. The mid-term outlook for IVD technology focuses on the proliferation of personalized medicine driven by genetic and molecular diagnostics. Advances in genomics and proteomics will lead to the development of more targeted diagnostics, enabling tailored treatment plans for individual patients. This period will witness a surge in the utility of liquid biopsies for cancer detection and monitoring, offering a less invasive alternative to traditional biopsy methods. Additionally, the integration of big data analytics will improve the predictive capabilities of diagnostic tools, facilitating early detection of diseases. In the long term, the frontier of IVD technology is expected to be transformed by the advent of nanotechnology and lab-on-a-chip devices, which will drastically reduce the volume of samples needed and the time required for analysis. Breakthroughs in biomarker discovery will enhance the sensitivity and specificity of diagnostics across a range of conditions. The ultimate goal will be achieving fully automated, highly accurate diagnostics that can be seamlessly incorporated into daily life, perhaps through wearable technology, enabling continuous health monitoring and early intervention for diseases.
